RxDoctor Payments Data

Svetomir Markovic, MD

Medical Oncology · Rochester, MNNPI 1013981257

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,206 of the $1,232 with a category attached, or 97.8%. E.r. Squibb & Sons, L.L.C. accounts for 99.0% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in MN, where the typical reported total is $1,006.

$1,232in general payments, 2019–2025

Across 7 payments — averaging $176.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$12
$1,389,487in research payments, 2019–2025

Across 19 payments — averaging $73,131 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$1.3M
  • Seagen Inc.$44K
  • Novartis$6K
  • Bristol Myers Squibb$1K

What the payments were for

  • Travel & lodging$1,20698%
  • Food & beverage$151%
  • Education$121%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.6$1,220
Novartis1$12

How this compares

$1,232 in reported general payments places this provider in the 50th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$430,673
Medicare patients
150
Services billed
14,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LeukineSargramostim13$58,206
Prednisone28$245
Levothyroxine Sodium12$211

Paid to pharmacies, not to this prescriber.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →